Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia

Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia - The Optimed study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON48168

Enrollment

Registered

2019-04-17

Start date

2019-06-24

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAH congenital adrenal hyperplasia

Interventions

After the informed consent procedure, each patient will receive the same total daily medication dosage from their own initial pre-study treatment, starting with either the highest dosage of hydrocor

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: * Children with congenital adrenal hyperplasia due to 21 hydroxylase deficientie * Age between 4 and 18 years * Able to collect saliva

Exclusion criteria

Exclusion criteria: * Other forms of CAH * Not able to collect saliva * Chronical medication use other than related to CAH

Design outcomes

Primary

Measure	Time frame
Concentrations of salivary 17OHP and A after 3 weeks of treatment with the 2 different timing strategies.	—

Secondary

Measure	Time frame
12 hours blood pressure and activity and sleeping patterns during the 2 treatment strategies.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)